Clinical trials: Neoadjuvant Treatment
Breast Cancer, Breast Cancer Female
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer
- Trial name
- NCT03387553
- Testing
- Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Hepatocellular Carcinoma
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in neoadjuvant of resectable Hepatocellular Carcinoma.
- Trial name
- NCT06512467
- Testing
- Donafenib, Sintilimab, HAIC
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Hepatocellular Carcinoma, Liver Cirrhosis
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver
The purpose of this study is to assess the safety of transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with hepatocellular carcinoma
- Trial name
- TRYPHON (NCT01686880)
- Testing
- Sirsphere trans-arterial radioembolization
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- Jules Bordet Institute
Bladder (Urothelial, Transitional Cell) Cancer
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment.
- Trial name
- NCT07119996
- Testing
- Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer
Neoadjuvant chemotherapy (NAC) is frequently proposed to patients with large tumours that can be operated in order to increase the chances of breast conservation.
- Trial name
- GANEA2 (NCT01221688)
- Testing
- Axillar Sentinel lymph node biopsy, SLNB and complete level I-II axillary lymphadenectomy
- Where
- 18 sites in France
- Volunteers
- 958 people
- Sponsor
- Institut Cancerologie de l'Ouest
Non-small Cell Lung Cancer
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage…
- Trial name
- KANDLELIT-013 (NCT07431827)
- Testing
- Calderasib, MK-3475A
- Where
- 120 sites in Argentina, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT02713386
- Testing
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate
- Where
- 110 sites in United States
- Volunteers
- 147 people
- Sponsor
- NRG Oncology
Neoadjuvant Radiotherapy, Breast Cancer
Neoadjuvant Radiotherapy for Breast Cancer
The goal of this clinical trial is to compare the effects of neoadjuvant radiotherapy and adjuvant radiotherapy in patients with breast cancer.
- Trial name
- NCT06313073
- Testing
- Neoadjuvant radiotherapy, adjuvant radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Breast Cancer
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
This is a single-center, randomized, open-label, phase II interventional study. Eligible patients will be randomized 1:1 to receive either Trastuzumab-rezetecan (4.8 mg/kg Q3W) or T-DXd (5.4 mg/kg Q3W) for 8 neoadjuvant cycles.
- Trial name
- NCT07416253
- Testing
- Trastuzumab rezetecan, Trastuzumab deruxtecan
- Volunteers
- 68 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer, Peritoneal Metastases
HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy
Patients with stage cT3-4N+M0 gastric cancer were recommended to receive neoadjuvant chemotherapy before radical surgery in terms of the eradication of micrometastasis in addition to local control, higher compliance with…
- Trial name
- NCT05300945
- Testing
- HIPEC
- Volunteers
- 200 people
- Sponsor
- Zhixin Cao
Prostate Cancer
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer
In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day.
- Trial name
- NCT05522907
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Resectable Non-small Cell Lung Cancer, Bispecific Antibody
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
The advent of immunotherapy has changed the treatment landscape for patients with non-small cell lung cancer. It has become the mainstay of perioperative treatment for patients with resectable non-small cell lung cancer。…
- Conditions
- Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy
- Trial name
- Neoadjuvant (NCT06946836)
- Testing
- AK104
- Volunteers
- 80 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate
- Trial name
- CAPT-02 (NCT06172036)
- Testing
- irinotecan liposome + oxaliplatin + 5-FU / LV, Adebellizumab
- Volunteers
- 180 people
- Sponsor
- Zhejiang University
Rectal Cancer, Metastatic
Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT03022734
- Testing
- chemotherapy, radiotherapy
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
DMMR Colorectal Cancer, Anti PD-1
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
According to the cancer statistics in 2020, colorectal cancer (CRC) remains a major public health issue worldwide, representing the third common cancer (10%) and second leading cause of death (9.4%) with 5-year survival rate…
- Conditions
- DMMR Colorectal Cancer, Anti PD-1, Immunotherapy
- Trial name
- NCT06262581
- Testing
- Tisleizumab(BGB-A317)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled phase II clinical trial.It plans to enroll a total of 24 eligible patients with locally advanced gastric/gastroesophageal junction adenocarcinoma who are HER2-positive…
- Trial name
- NCT07716111
- Testing
- Trastuzumab Rezatecan and Retlirafusp alfa, Trastuzumab Rezatecan and Retlirafusp alfa+Pertuzumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Ovarian Cancer (Stage III or IV) After Neoadjuvant Chemotherapy
LYmphadenectomy After NeoAdjuvant Chemotherapy
The purpose of this study is to determine the role of lymphadenectomy in advenced ovarian cancer patients at the time of interval debulking surgery after neoadjuvant chemiotherapy.
- Trial name
- LYANA (NCT01724944)
- Testing
- Systematic pelvic and aortic lymphadenectomy
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- Catholic University of the Sacred Heart
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.